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Abstract
The chitinase-like protein YKL-40 was found to be increased in patients with severe asthma and chronic obstructive
pulmonary disease (COPD), two disease conditions featuring neutrophilic infiltrates. Based on these studies and a previous
report indicating that neutrophils secrete YKL-40, we hypothesized that YKL-40 plays a key role in cystic fibrosis (CF) lung
disease, a prototypic neutrophilic disease. The aim of this study was (i) to analyze YKL-40 levels in human and murine CF
lung disease and (ii) to investigate whether YKL-40 single-nucleotide polymorphisms (SNPs) modulate CF lung disease
severity. YKL-40 protein levels were quantified in serum and sputum supernatants from CF patients and control individuals.
Levels of the murine homologue BRP-39 were analyzed in airway fluids from CF-like bENaC-Tg mice. YKL-40SNPs were
analyzed in CF patients. YKL-40 levels were increased in sputum supernatants and in serum from CF patients compared to
healthy control individuals. Within CF patients, YKL-40 levels were higher in sputum than in serum. BRP-39 levels were
increased in airways fluids from bENaC-Tg mice compared to wild-type littermates. In both CF patients and bENaC-Tg mice,
YKL-40/BRP-39 airway levels correlated with the severity of pulmonary obstruction. Two YKL-40 SNPs (rs871799 and
rs880633) were found to modulate age-adjusted lung function in CF patients. YKL-40/BRP-39 levelsare increased in human
and murine CF airway fluids, correlate with pulmonary function and modulate CF lung disease severity genetically. These
findings suggest YKL-40 as a potential biomarker in CF lung disease.
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Introduction
Chronic lung disease determines the morbidity and mortality of
cystic fibrosis (CF) patients [1]. CF lung disease is characterized by
a nonresolving neutrophilic inflammation with impaired antibac-
terial killing and proteolytic destruction of pulmonary tissue [2].
Humans lack chitin, but they express chitinases and chitinase-
like proteins (CLP). Both chitinases and CLP belong to the 18-
glycosyl-hydrolase family, including acidic mammalian chitinase
(AMCase), chitotriosidase, oviductin, YKL-40 in humans, while
YM-1, YM-2, AMCase, oviductin, and breast regression protein
(BRP-39) have been described in mice. CLPs bind chitin, but do
not have enzymatic chitinase activity due to mutations in their
highly conserved putative enzyme sites [3]. The prototypical CLP
YKL-40 (YKL for the first three N-terminal residues of a 40 kDa
protein, also termed human cartilage glycoprotein (HcGP)-39)
gene is localized on chromosome 1 [4]. The murine homologue of
YKL-40 is breast regression protein of 39 kDa (BRP-39). YKL-
40/BRP-39 was initially described to be expressed in cancer cells
and several lines of evidence support the view that YKL-40/BRP-
39 plays a role in cell proliferation, survival and tissue remodeling
[5–7].
YKL-40 protein levels are detectable in human serum and were
unexpectedly found to be significantly increased in patients with
severe asthma [8] and chronic obstructive pulmonary disease
(COPD) [9], two disease conditions featuring neutrophilic
infiltrates. Based on these studies and a previous report indicating
that neutrophils secrete YKL-40 [21], we hypothesized that YKL-
40 plays a key role in CF lung disease, a prototypic neutrophilic
disease.
We quantified YKL-40 protein levels in serum and airway fluids
(sputum supernatants) from individuals with CF and control
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lung function in a mouse model of CF-like lung disease (bENaC-
Tg mice) and analyzed the impact of YKL-40 gene variants on
YKL-40 protein levels and age-adjusted CF lung disease severity.
Materials and Methods
Patient cohorts
In total, 338 CF patients were included in the study (see
genotyping cohort below, Methods S1 and Table S1). Out of this
cohort we were able to collect both peripheral blood and induced
sputum ex vivo sample material simultaneously from 59 patients in
order to quantify YKL-40 protein levels. Accordingly, YKL-40
protein levels were analyzed in serum and induced sputum
supernatants of patients with CF (n=59) and healthy control
subjects (n=26) (Table 1). The CF group included 31 male and 28
female patients with a mean age of 22615 (SD) years. Inclusion
criteria were the diagnosis of CF by clinical symptoms and positive
sweat tests (sweat Cl- concentration .60 mmol/l) or disease-
causing mutations in the CFTR gene, forced expiratory volume in
1 second (FEV1) .30% of predicted value [31,32] and being
clinically stable and on steady concomitant therapy at least four
weeks prior to the study. Genetically, 34 CF patients were DF508
homozygous, 19 were DF508 heterozygous carriers of the CFTR
gene and 6 had other CFTR mutations than DF508.Twenty-six
control subjects without pulmonary diseases were selected as the
control group (12 male, 14 female; mean age: 2569 SD years).
These subjects had no suspected or proven pulmonary disease and
were free of respiratory tract infections [30]. Informed written
consent was obtained from all subjects included in the study or their
parents, and all study methods were approved by the local ethics
committee (Ethics committee of the Ludwig-Maximilians-Univer-
sity (LMU), Munich, Germany) and by the institutional review
board of the Children’s Hospital of the Ludwig-Maximilians-
University, Munich, Germany. Induced sputum was obtained,
processed and stored as described previously [22,33]. Cell-free
sputum supernatant was stored at 280uC until analysis.
Experimental animals
The generation of bENaC-Tg mice has been previously described
[36]. Animal studies of the betaENaC-Tg mice (ID 6608) were
approved by the Regierungspra ¨sidium Karlsruhe or by the
Regierung von Oberbayern, Munich, Germany. The colony was
maintained on a mixed genetic background (C3H/HeN6C57BL/
6N), and bENaC-Tg mice were identified by PCR. Wild-type
littermates served as controls in all experiments. Mice were housed in
a pathogen-free animal facility and had free access to chow and
water. For further details please refer to the Supplementary section.
For bronchoalveolar lavage (BAL) mice were deeply anesthetized via
intra-peritoneal injection of a combination of ketamine/xylazine
(120 mg/kg and 16 mg/kg, respectively), the trachea was cannulated
and lungs were carefully lavaged twice with 800 mlP B S .B R P - 3 9
protein levels were measured in BAL supernatant using aR&D
System’s ELISA. Total cell counts were determined and differential
cell counts performed on cytospin preparations. Studies were
performed by investigators who were blinded with respect to the
genotype. We used two different invasive pulmonary function devices
(both from Buxco Research Systems; Wilmington, NC): a forced
maneuver system and a FinePointe RC system. Mouse pulmonary
function testing was performed and analyzed as published previously
[37]. All mice were anesthetized with i.p. MMF (Medetomidin,
Midazolam, Fentanyl), intubated and placed in a FinePointe RC
system. In a heated plethysmograph chamber, mice were ventilated
at an average rate of 140 breaths per minute, and flow, mouth and
esophageal pressure and heart rate were monitored to measure
resistance and dynamic compliance. After an initial acclimation
period of three minutes, two subsequent one-minute measurements
were performed and averaged. After the resistance and compliance
measures, mice were transferred to a forced pulmonary maneuvers
system. Quasistatic pressure volume and fast flow volume maneuvers
were run three times each and averaged to obtain forced expiratory
volumeat 100 ms,forced vital capacity and chordcompliance values.
ELISA
YKL-40 and BRP-39 protein levels were measured in duplicates
by a commercially available, sandwich enzyme-linked immuno-
sorbent assay (ELISA) kit (R&D Systems) according to the
manufacturer’s instructions.
Genotyping cohort
Polymorphisms were genotyped in a CF population (Tables S1
and S2) to investigate the influence of single nucleotide
polymorphisms (SNPs) [34] on CF lung disease. Informed written
consent was obtained from all subjects included in the study or
their parents, and all study methods were approved by the local
ethics and by the institutional review board. For more details see
ONLINE SUPPLEMENT.
Statistical analysis
Differences between the patient groups were calculated using
the non-parametric Kruskal-Wallis test. When a significant
difference was found, the non-parametric Mann-Whitney U test
was applied for two-group comparisons. Correlations were verified
with Spearman rho test. Associations between SNPs and qualitative
outcomes were tested by using Pearson X
2 tests [35]. A P value of
,0.05 was considered to be significant. A correlation was assumed
when the correlation coefficient was .0.3. Statistical analysis was
performed with Prism 4.0 (Graph Pad Software, San Diego, CA,
USA) and STATA version 8.2 for Windows (STATA Corpora-
tion, College Station, TX, USA).
Results
Increased YKL-40/BRP-39 levels in human and murine
cystic fibrosis airway fluids
YKL-40 levels were significantly increased in both sputum
supernatants and serum from CF patients compared to healthy
Table 1. Patient groups.
Cystic fibrosis Controls
N5 9 2 6
Age [yrs] 22615 2569
Sex (m:f) 31/28 12/14
WBC (10
9/l) 10658 63
FEV1 (% pred) 63615 -
Neutrophils in sputa (%) 83632 17610
P. aeruginosa{ 35 0
Antibiotics 35 0
dF508homozygous/heterozygous/other 34/19/6 n.d.
Results are expressed as means 6 SD; m: male, f: female; WBC: white blood
count; FEV1: Forced expiratory volume in 1 second (% of predicted);
{P. aeruginosa bacteria isolated in at least 2 consecutive sputum samples with a
minimum of a 6-month interval; n.d. not determined.
doi:10.1371/journal.pone.0024399.t001
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YKL-40 protein levels were consistently higher in sputum than in
serum. Notably, YKL-40 levels in CF sputa and CF sera showed a
broad range of detection from levels similar to healthy control
levels up to 30-fold higher levels in CF patients compared to
healthy controls (Figure 1A right graph).YKL-40 serum levels
correlated positively with YKL-40 sputum levels in both CF
patients (r=0.69, p,0.01) and, to a lesser extent, healthy control
individuals (r=0.42, p,0.05). Sputum levels of YKL-40 correlat-
ed positively with numbers of neutrophils in sputa (r=0.74,
p,0.01), but not with numbers of eosinophils(r=0.13, p.0.05),
lymphocytes(r=0.18, p.0.05) or macrophages (r=0.10, p.0.05).
Consistent with human CF lung disease, protein levels of the
murine YKL-40 homologue BRP-39 were highly increased in
bronchoalveolar lavage fluid (BALF) from bENaC-Tg mice
compared to BALF from WT mice (Figure 1B). Both in human
CF patients as well as in murine CF lung disease, YKL-40/BRP-
39 airway levels correlated with airflow obstruction in pulmonary
functions tests (FEV1 and resistance, respectively, Figure 1C), but
not with parameters of pulmonary restriction (data not shown).
When viewed in combination, these studies demonstrate that
YKL-40/BRP-39 levels are increased in CF patients and a mouse
model of CF-like lung disease, and are associated with obstructive
pulmonary function.
Figure 1. YKL-40 levels in human and murine CF lung disease. A. YKL-40 levels in CF patients and healthy controls YKL-40 protein levels were
quantified by means of ELISA in sera and sputum supernatants from cystic fibrosis (CF) or healthy control subjects. The left graph depicts means 6
SDs, the right scatter graph depicts individual patients with horizontal bars as medians; *P,0.05 ** P,0.01 disease group compared to the control
group. Horizontal bars indicate comparisons among the disease groups. B. BRP-39 levels in murine CF-like lung disease. BRP-39 protein levels were
quantified by means of ELISA in BAL fluids from bENaC-Tg (n=9) and WT mice (n=7). *P,0.05; C. YKL-40/BRP-39 airway levels and lung function in
human and murine CF lung disease. Left panel: YKL-40 protein levels were quantified by means of ELISA in sputum supernatants from CF patients
(n=59). FEV1: Forced expiratory volume in 1 second (% of predicted). Right panel: BRP-39 protein levels were quantified by means of ELISA in BAL
fluids from bENaC-Tg (n=9, grey fill) and WT mice (n=7, white fill).
doi:10.1371/journal.pone.0024399.g001
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fibrosis lung disease severity
Based on the finding that both YKL-40 serum and sputum levels
showed a high extent of heterogeneity among CF individuals, we
investigated whether YKL-40 gene variants modulate YKL-40
serum levels and CF lung disease severity. Based on previous results
from YKL-40 SNP studies in asthmatics (11), we genotyped ten
candidate SNPs tagging the YKL-40 locus in a well-characterized
CF patient cohort (Table S2 and Figure 2A). Two YKL-40 SNPs,
located in the promoter (rs871799) and in the exon 5 (rs880633)
region, respectively, were found to modulate age-adjusted lung
function in CF patients (longitudinal FEV1age-adjusted at 20 years
according to the method described previously by Schluchter et al.
[19] (Table 2 and Figure 2A). Furthermore, the promoter SNPs
rs871799 and rs4950928 modulated YKL-40 serum levels
(Figure 2B). These studies demonstrate that YKL-40 gene variants
areassociated withYKL-40serum levelsand pulmonary function in
CF patients.
Discussion
CF lung disease is characterized by a vicious cycle of
neutrophilic inflammation, infection and tissue remodeling.
Despite an increasing body of evidence on infectious and
inflammatory mechanisms contributing to CF lung disease [20],
Figure 2. YKL-40 SNPs. A. Location and linkage disequilibrium (R
2)o fYKL-40 polymorphisms genotyped in the CF population. B. YKL-40 serum
levels in CF patients stratified for the respective rs871799 (upper panel) or the rs4950928 (lower panel) genotype. *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0024399.g002
Table 2. Association test results for YKL-40 SNPs.
SNP Position Location Alleles MAF FEV1% @20 yrs#70 MAF FEV1% @20 yrs.70 OR* Pvalue
rs871799 214,120 Promoter C/G 0.113 0.192 0.24 0.043
rs2153101 212,723 Promoter T/A 0.215 0.189 1.31 0.711
rs946263 29,630 Promoter A/G 0.144 0.138 0.73 1.000
rs4950929 24,374 Promoter T/G 0.215 0.200 0.82 1.000
rs6691378 21,371 Promoter G/A 0.136 0.154 1.78 0.469
rs10399805 2247 Promoter G/A 0.156 0.178 1.11 1.000
rs4950928 2131 Promoter C/G 0.226 0.183 1.09 1.000
rs1538372 +1,220 Intron 2 G/A 0.371 0.337 0.94 1.000
rs880633 +2,951 Exon 5 T/C 0.419 0.522 0.46 0.016
rs2275352 +5,573 Intron 7 G/A 0.188 0.154 0.71 1.000
*recessive model; MAF, minor allele frequency; FEV1%@20 yrs, age-adjusted (at 20 years) longitudinal forced expiratory volume (FEV1) (19); OR, odds ratio.
doi:10.1371/journal.pone.0024399.t002
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may serve as biomarkers are yet poorly defined. The CLP YKL-40
is induced at sites of inflammation, and previous studies suggested
a role for this ancient glycoprotein as biomarker and potential
therapeutic target in asthma [8,18] and COPD [9]. It remained,
however, elusive whether the accumulation of YKL-40 is specific
for these disease conditions or whether YKL-40 increase reflects
chronic pulmonary inflammation. In particular, the role of YKL-
40 in CF lung disease has not been characterized so far. Here we
demonstrate that YKL-40 protein levels are highly increased in the
airways of patients and mice with CF lung disease and correlate
with neutrophilic inflammation and airflow obstruction. Similar as
in asthma, YKL-40 serum levels in CF patients were regulated
genetically by promoter SNPs [11].
Previous studies found increased YKL-40protein levels and
expression, respectively, in the circulation and lung from patients
with severe asthma [8] and COPD [9]. Recently, YKL-40 has
been described to play a role in hyperoxia-induced acute lung
injury [10]. YKL-40 has also been implicated in a variety of non-
pulmonary inflammatory diseases, such as rheumatoid arthritis
[12], systemic sclerosis [13], myocardial infarction [14], meningi-
tis[15], diabetes [16] and cancer[17]. We found that increased
YKL-40 levels correlated with neutrophilic cellular infiltrate in CF
patients. This finding may correspond to the results from Chupp et
al. demonstrating that YKL-40 serum levels were particularly
increased in severe asthma, a disease phenotype frequently
featuring a more pronounced neutrophilic than eosinophilic
airway infiltrate associated with corticosteroid resistance. Given
this latter study and our present data, it remains to be investigated
in future studies whether increased YKL-40 serum/airway levels
are restricted to asthma subtypes with a pronounced neutrophilic
inflammation.
The question arises which factors underlie the highly increased
YKL-40 levels in CF patients. We speculate that YKL-40 levels in
CF reflect the extent of neutrophilic airway inflammation rather
than being modulated directly by the genetic CF defect (Cystic
Fibrosis Transmembrane Conductance, CFTR). Neutrophils have
been reported to store YKL-40 intracellularly in their secondary
granules [21] and CF airway neutrophils were consistently found
to express CD66b [23], indicating post-activation and release of
secondary granules. YKL-40 protein levels in our study were
highest in CF sputa, where numerous activated neutrophils
accumulate, whereas in CF sera only moderately increased levels
were found. At rising YKL-40 airway levels, the CLP may leak out
into the circulation, explaining the increased levels found in serum
of CF patients. Nevertheless, CFTR deficient neutrophils may
intrinsically release more YKL-40 than control cells, a hypothesis
that should be addressed in future studies.
The promoter SNP rs4950928 in the YKL-40 gene was
previously found to modulate YKL-40 serum levels and asthmatic
lung disease severity [11]. Our studies demonstrated that two YKL-
40 SNPs (rs871799 and rs880633), located in the promoter region
or exon 5, respectively, modulated age-adjusted lung function [19]
in CF patients. Consistent with the previous study in asthmatics
[11], we found that rs4950928 affected YKL-40 serum levels, but
differently in our CF cohort, rs4950928 variants had no
association with lung function in CF patients. Besides rs4950928,
we identified a second promoter SNP (rs871799) that affected
YKL-40 serum levels in CF patients. Based on previously
published studies [11] and the herein described genetic studies,
we suggest that at least two distinct promoter SNPs modulate
YKL-40 serum levels in CF patients. We further speculate that
rs871799 could be involved in both regulating YKL-40 serum
levels and modulating FEV1, while rs880633 may affect YKL-40
functionality that, in turn, may modulate pulmonary CF disease
(FEV1), without regulating YKL-40 expression and protein
(serum) levels. Beyond that, the impact of YKL-40 SNPs on lung
function might depend on the type of pulmonary disease
pathology (Th2-driven asthmatic versus CF lung disease). Within
asthmatics, severe neutrophil-associated asthma may represent a
distinct entity featuring increased YKL-40 levels [24,25].
Despite significant processes in the field of chitinase-like proteins
in the last years, including generation and characterization of
transgenic mouse models, the biological and pathophysiological
function of secreted YKL-40 in pulmonary diseases remains
enigmatic [26–28]. Based on previous studies, using a genetic brp-
39 knock-out and a humanized YKL-40 transgenic overexpressing
mouse, demonstrating that YKL-40/BRP-39 plays a role in tissue
remodeling, cell death pathway regulation and airway obstruction
[29],we speculate that released YKL-40 contributes to the cellular
homeostasis and tissue remodeling, thereby modulating pulmo-
nary function and inflammation in CF. However, additional
studies focused on the functionality of YKL-40 in the CF
microenvironment are required to understand the pathophysio-
logical mechanisms linking YKL-40 and CF airway inflammation.
In summary, our studies demonstrated increased airway levels
of the chitinase-like protein YKL-40 in CF patients compared to
control individuals. This finding in CF patients could be
corroborated by studies in a CF-like murine disease model. In
both human and murine CF airway fluids, YKL-40/BRP-39 levels
correlated with lung function, suggesting that increased YKL-40/
BRP-39 levels may have an impact on airway obstruction in CF
patients. These results suggest YKL-40 levels in sputum as
potential biomarker of neutrophilic airway inflammation in CF.
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